Elizabeth L. Barry, PhD
Associate Professor of Epidemiology
Associate Professor of Community and Family Medicine
Community and Family Medicine
Dartmouth College CECS, MS
University of Wisconsin-Madison, PhD
Grinnell College, BA
Norris Cotton Cancer Center
Quantitative Biomedical Sciences
One Medical Center Drive
Rubin Building, Room 857
Lebanon NH 03756
Office: Room 857
Dr. Barry's current research focuses on the chemoprevention of cancer and the pharmacogenetics of chemopreventative agents. She is especially interested in the role and mechanism of action of anti-inflammatory drugs (such as aspirin) and nutritional supplements (such as calcium, vitamin D and folate) as chemopreventative agents for cancer. Using data from clinical trials, Dr. Barry is currently investigating how genetic polymorphisms may modify the effectiveness of some of these drugs in the prevention of colorectal adenomas. In addition to her interest in cancer, Dr. Barry has a long-standing interest in calcium and vitamin D regulation and their role in bone health and disease (osteoporosis).
Medical Pharmacology (Calcium and Bone Pharmacology)
Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial.
Validation of a genetic-enhanced risk prediction model for colorectal cancer in a large community-based cohort.
Alterations in Fecal Short-Chain Fatty Acids after Bariatric Surgery: Relationship with Dietary Intake and Weight Loss.
Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal Adenomas.
Predictors of Incident Serrated Polyps: Results from a Large Multicenter Clinical Trial.
Association of demographic and health characteristics with circulating oxysterol concentrations.
Proliferation, apoptosis and their regulatory protein expression in colorectal adenomas and serrated lesions.
Circulating Sex Hormones and Risk of Colorectal Adenomas and Serrated Lesions in Men.
Oral Antibiotics and Risk of New Colorectal Adenomas During Surveillance Follow-up.
Circulating 27-hydroxycholesterol and Risk of Colorectal Adenomas and Serrated Polyps.